PT Millennium Pharmacon International Tbk (ISX:SDPC) Piotroski F-Score: 7 (As of Sep. 16, 2026) — 75% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISX:SDPC PT Millennium Pharmacon International Tbk ISX:SDPC
78 GF Score
Price Rp197.00
GF Value Rp171.08
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is PT Millennium Pharmacon International Tbk Piotroski F-Score?

PT Millennium Pharmacon International Tbk ISX:SDPC -0.51% 78 Piotroski F-Score is 7 as of Sep. 16, 2026, which is 75% above its 10-year median of 4.00. GuruFocus rates ISX:SDPC with a GF Score™ of 78/100 and a GF Value™ of Rp171.08 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 117 Medical Distribution companies, PT Millennium Pharmacon International Tbk ranks better than 90.6% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PT Millennium Pharmacon International Tbk has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for PT Millennium Pharmacon International Tbk's Piotroski F-Score or its related term are showing as below:

ISX:SDPC' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of PT Millennium Pharmacon International Tbk was 8. The lowest was 1. And the median was 4.

PT Millennium Pharmacon International Tbk  (ISX:SDPC) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


PT Millennium Pharmacon International Tbk Piotroski F-Score Related Terms


PT Millennium Pharmacon International Tbk Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for PT Millennium Pharmacon International Tbk's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Millennium Pharmacon International Tbk Piotroski F-Score Chart

PT Millennium Pharmacon International Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 6.00 4.00 3.00 6.00

PT Millennium Pharmacon International Tbk Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.00 6.00 6.00 7.00

ISX:SDPC vs MCK, COR, CAH: Piotroski F-Score Comparison

For the Medical Distribution subindustry, PT Millennium Pharmacon International Tbk's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Millennium Pharmacon International Tbk Piotroski F-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, PT Millennium Pharmacon International Tbk's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where PT Millennium Pharmacon International Tbk's Piotroski F-Score falls into.


ISX:SDPC
78GF Score
PT Millennium Pharmacon International Tbk ISX:SDPC
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was 3640.372806 + 18083.329534 + 10104.641692 + 9457.641909 = Rp41,286 Mil.
Cash Flow from Operations was -35321.54352 + 71798.857761 + -60984.544857 + -101387.861208 = Rp-125,895 Mil.
Revenue was 1059492.176392 + 1107635.38664 + 1017973.008426 + 1113228.40532 = Rp4,298,329 Mil.
Gross Profit was 79578.553855 + 99157.366934 + 82574.30955 + 90482.308258 = Rp351,793 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(1886713.384072 + 1903703.235741 + 1960719.855135 + 2015047.454454 + 2101208.70159) / 5 = Rp1973478.5261984 Mil.
Total Assets at the begining of this year (Jun25) was Rp1,886,713 Mil.
Long-Term Debt & Capital Lease Obligation was Rp49,696 Mil.
Total Current Assets was Rp1,868,752 Mil.
Total Current Liabilities was Rp1,684,307 Mil.
Net Income was 5137.939843 + -3557.337299 + 10333.759208 + 6411.45044 = Rp18,326 Mil.

Revenue was 983825.881225 + 992752.886758 + 980187.38 + 962495.395984 = Rp3,919,262 Mil.
Gross Profit was 79235.1022 + 75862.102806 + 83002.973658 + 77219.583586 = Rp315,320 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(1805644.662788 + 1783742.469541 + 1771856.829401 + 1796505.250451 + 1886713.384072) / 5 = Rp1808892.5192506 Mil.
Total Assets at the begining of last year (Jun24) was Rp1,805,645 Mil.
Long-Term Debt & Capital Lease Obligation was Rp47,199 Mil.
Total Current Assets was Rp1,662,940 Mil.
Total Current Liabilities was Rp1,507,458 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PT Millennium Pharmacon International Tbk's current Net Income (TTM) was 41,286. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PT Millennium Pharmacon International Tbk's current Cash Flow from Operations (TTM) was -125,895. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=41285.985941/1886713.384072
=0.02188249

ROA (Last Year)=Net Income/Total Assets (Jun24)
=18325.812192/1805644.662788
=0.01014918

PT Millennium Pharmacon International Tbk's return on assets of this year was 0.02188249. PT Millennium Pharmacon International Tbk's return on assets of last year was 0.01014918. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

PT Millennium Pharmacon International Tbk's current Net Income (TTM) was 41,286. PT Millennium Pharmacon International Tbk's current Cash Flow from Operations (TTM) was -125,895. ==> -125,895 <= 41,286 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=49696.07641/1973478.5261984
=0.02518197

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=47198.906656/1808892.5192506
=0.02609271

PT Millennium Pharmacon International Tbk's gearing of this year was 0.02518197. PT Millennium Pharmacon International Tbk's gearing of last year was 0.02609271. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=1868751.807504/1684307.428119
=1.10950755

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=1662940.250448/1507457.684539
=1.10314224

PT Millennium Pharmacon International Tbk's current ratio of this year was 1.10950755. PT Millennium Pharmacon International Tbk's current ratio of last year was 1.10314224. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

PT Millennium Pharmacon International Tbk's number of shares in issue this year was 1274. PT Millennium Pharmacon International Tbk's number of shares in issue last year was 1274. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=351792.538597/4298328.976778
=0.08184402

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=315319.76225/3919261.543967
=0.08045387

PT Millennium Pharmacon International Tbk's gross margin of this year was 0.08184402. PT Millennium Pharmacon International Tbk's gross margin of last year was 0.08045387. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=4298328.976778/1886713.384072
=2.27820983

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=3919261.543967/1805644.662788
=2.17056081

PT Millennium Pharmacon International Tbk's asset turnover of this year was 2.27820983. PT Millennium Pharmacon International Tbk's asset turnover of last year was 2.17056081. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+1+1+1+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PT Millennium Pharmacon International Tbk has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
PT Millennium Pharmacon International Tbk (ISX:SDPC) has a Piotroski F-Score of 7 as of Sep. 16, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PT Millennium Pharmacon International Tbk and its competitors. This is 75% above median its historical median of 4.00. Over the past decade, PT Millennium Pharmacon International Tbk's Piotroski F-Score has ranged from 1.00 to 8.00. According to the industry distribution chart, PT Millennium Pharmacon International Tbk ranks #11 out of 117 companies in the Medical Distribution industry, placing it in the top 9.4%.
Is PT Millennium Pharmacon International Tbk's Piotroski F-Score too high?
PT Millennium Pharmacon International Tbk's current Piotroski F-Score of 7 is 75% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. The Medical Distribution industry median Piotroski F-Score is 5.00. PT Millennium Pharmacon International Tbk's value of 7 is 40% above this industry median. Based on the distribution chart, PT Millennium Pharmacon International Tbk ranks #11 out of 117 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, PT Millennium Pharmacon International Tbk has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PT Millennium Pharmacon International Tbk's Piotroski F-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Millennium Pharmacon International Tbk ranks #11 out of 117 companies for Piotroski F-Score. This places PT Millennium Pharmacon International Tbk in the top 9% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. PT Millennium Pharmacon International Tbk's value of 7 is 40% above this benchmark. Historically, PT Millennium Pharmacon International Tbk's own Piotroski F-Score has ranged from 1.00 to 8.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, PT Millennium Pharmacon International Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Distribution company?
The median Piotroski F-Score among Medical Distribution companies is 5.00, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Millennium Pharmacon International Tbk's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PT Millennium Pharmacon International Tbk and its competitors. For the Medical Distribution industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Millennium Pharmacon International Tbk's current Piotroski F-Score is 7, which is 75% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Millennium Pharmacon International Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk (ISX:SDPC) is currently considered Modestly Overvalued. The stock's GF Value™ is Rp171.08, compared to a current price of Rp197.00 — trading 15.2% above its estimated fair value. The current Piotroski F-Score is 7, which is 75% above median its 10-year median of 4.00 and 40% above the Medical Distribution industry median of 5.00. PT Millennium Pharmacon International Tbk's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For PT Millennium Pharmacon International Tbk (ISX:SDPC), the current Piotroski F-Score is 7 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Millennium Pharmacon International Tbk (ISX:SDPC) Overvalued in 2026?

Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk stock appears to be overvalued. The current stock price of Rp197.00 is trading 15.2% above its estimated GF Value™ of Rp171.08. GuruFocus considers PT Millennium Pharmacon International Tbk to be Modestly Overvalued.

Key valuation signals for ISX:SDPC:

  • Piotroski F-Score: 7 (75% above median its 10-year median of 4.00)
  • GF Value™: Rp171.08 vs. price of Rp197.00 (15.2% above fair value)
  • GF Score™: 78/100 with 6 warning signs
  • Industry Position: 40% above the Medical Distribution median (#11 of 117)

No single metric tells the full story. See the ISX:SDPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PT Millennium Pharmacon International Tbk Business Description

Address Jl. Sultan Iskandar Muda No 18/Jl. Bungur No. 1, Crown Bungur Arteri Lantai 2-4, Kel. Kebayoran Lama Selatan, Kec. Kebayoran Lama, South Jakarta, Jakarta, IDN, 12240
PT Millennium Pharmacon International Tbk is engaged in distributing medicines, food supplements, and medical disposables. The group's operating segments are Prescription medicine, Non-prescription medicine, Medical Disposables, and others, of which the majority of revenue is derived from the Prescription Medicine segment. The company's geographical segments are Jawa, Sumatra, Kalimantan, Sulawesi, and Bali & Lombok.
78GF Score

Get the complete analysis for ISX:SDPC

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp197.00
Price
Rp171.08
GF Value